Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits

DMM Disease Models and Mechanisms

Volumn 7, Issue 11, 2014, Pages 1263-1273

  Bielohuby, Maximilian ^a   Zarkesh Esfahani, Sayyed Hamid ^b,c,d   Manolopoulou, Jenny ^e   Wirthgen, Elisa ^f   Walpurgis, Katja ^g   Khorasgani, Mohaddeseh Toghiany ^c   Aghili, Zahra Sadat ^b   Wilkinson, Ian Robert ^d   Hoeflich, Andreas ^h   Thevis, Mario ^g   Ross, Richard J ^d   Bidlingmaier, Martin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ISFAHAN   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e Immunodiagnostic Systems Ltd (IDS Ltd)   (United Kingdom)

^f Ligandis GbR   (Germany)

^g GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^h LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

Author keywords

Acromegaly; Animal model; Growth hormone deficiency; Pharmacodynamic marker

Indexed keywords

BIOLOGICAL MARKER; PEGVISOMANT; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; GROWTH HORMONE; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HORMONE DETERMINATION; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PHARMACODYNAMICS; RABBIT; VALIDATION PROCESS; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; LIMIT OF DETECTION; METABOLISM; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RODENTIA;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; LIMIT OF DETECTION; RABBITS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84920062110     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.016519     Document Type: Article

References (55)

1. Bannink, E. M., van Doorn, J., Stijnen, T., Drop, S. L. and de Muinck Keizer-Schrama, S. M. (2006). Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment. Clin. Endocrinol. (Oxf.) 65, 310-319.
2. Berger, M., Jean-Faucher, C., de Turckheim, M., Veyssiere, G., Blanc, M. R., Poirier, J. C. and Jean, C. (1982). Testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) in plasma of rabbit from birth to adulthood. Correlation with sexual and behavioural development. Acta Endocrinol. (Copenh.) 99, 459-465.
3. Bidlingmaier, M., Friedrich, N., Emeny, R. T., Spranger, J., Wolthers, O. D., Roswall, J., Körner, A., Obermayer-Pietsch, B., Hübener, C., Dahlgren, J. et al. (2014). Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J. Clin. Endocrinol. Metab. 99, 1712-1721.
4. Bielohuby, M., Sawitzky, M., Stoehr, B. J., Stock, P., Menhofer, D., Ebensing, S., Bjerre, M., Frystyk, J., Binder, G., Strasburger, C. et al. (2011a). Lack of dietary carbohydrates induces hepatic growth hormone (GH) resistance in rats. Endocrinology 152, 1948-1960.
5. Bielohuby, M., Schaab, M., Kummann, M., Sawitzky, M., Gebhardt, R., Binder, G., Frystyk, J., Bjerre, M., Hoeflich, A., Kratzsch, J. et al. (2011b). Serum IGF-I is not a reliable pharmacodynamic marker of exogenous growth hormone activity in mice. Endocrinology 152, 4764-4776.
6. Bielohuby, M., Popp, S. and Bidlingmaier, M. (2013). Influence of pre-analytical conditions on the measurement of components of the GH/IGF axis in rats. Growth Horm. IGF Res. 23, 141-148.
7. Blum, W. F., Horn, N., Kratzsch, J., Jorgensen, J. O., Juul, A., Teale, D., Mohnike, K. and Ranke, M. B. (1993). Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul. 3, 100-104.
8. Clemmons, D. R. (2007). Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol. Metab. Clin. North Am. 36, 109-129.
9. Clemmons, D. R. (2011). Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555-559.
10. Costa, C., Solanes, G., Visa, J. and Bosch, F. (1998). Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus. FASEB J. 12, 1455-1460.
11. Courtland, H. W., Sun, H., Beth-On, M., Wu, Y., Elis, S., Rosen, C. J. and Yakar, S. (2011). Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production. J. Bone Miner. Res. 26, 761-768.
12. Cox, H. D., Lopes, F., Woldemariam, G. A., Becker, J. O., Parkin, M. C., Thomas, A., Butch, A. W., Cowan, D. A., Thevis, M., Bowers, L. D. et al. (2014). Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin. Chem. 60, 541-548.
13. D'Ercole, A. J., Bose, C. L., Underwood, L. E. and Lawson, E. E. (1984). Serum somatomedin-C concentrations in a rabbit model of diabetic pregnancy. Diabetes 33, 590-595.
14. Daniel-Carlier, N., Harscoët, E., Thépot, D., Auguste, A., Pailhoux, E. and Jolivet, G. (2013). Gonad differentiation in the rabbit: evidence of species-specific features. PLoS ONE 8, e60451.
15. Divisova, J., Kuiatse, I., Lazard, Z., Weiss, H., Vreeland, F., Hadsell, D. L., Schiff, R., Osborne, C. K. and Lee, A. V. (2006). The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res. Treat. 98, 315-327.
16. Domené, H., Krishnamurthi, K., Eshet, R., Gilad, I., Laron, Z., Koch, I., Stannard, B., Cassorla, F., Roberts, C. T., Jr and LeRoith, D. (1993). Growth hormone (GH) stimulates insulin-like growth factor-I (IGF-I) and IGF-I-binding protein-3, but not GH receptor gene expression in livers of juvenile rats. Endocrinology 133, 675-682.
17. Festoff, B. W. (1995). Proceedings of the Symposium on GHRH, GH and IGF-I: Basic and Clinical Advances. New York, NY: Springer-Verlag.
18. Flisikowska, T., Thorey, I. S., Offner, S., Ros, F., Lifke, V., Zeitler, B., Rottmann, O., Vincent, A., Zhang, L., Jenkins, S. et al. (2011). Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PLoS ONE 6, e21045.
19. Friedrich, N., Thuesen, B., Jorgensen, T., Juul, A., Spielhagen, C., Wallaschofksi, H. and Linneberg, A. (2012). The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 35, 768-773.
20. Friedrich, N., Wolthers, O. D., Arafat, A. M., Emeny, R. T., Spranger, J., Roswall, J., Kratzsch, J., Grabe, H. J., Hübener, C., Pfeiffer, A. F. et al. (2014). Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J. Clin. Endocrinol. Metab. 99, 1675-1686.
21. Fu, Y., He, X., Wang, Y. and Wang, B. (2007). Effects of xianzhong injection on the function of knee joint and the content of insulin-like growth factor-1 in rabbits of early osteoarthritis. J. Tradit. Chin. Med. 27, 288-292.
22. Gronbaek, H., Nielsen, B., Schrijvers, B., Vogel, I., Rasch, R. and Flyvbjerg, A. (2002). Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice. J. Endocrinol. 172, 637-643.
23. Grönbladh, A., Johansson, J., Nöstl, A., Nyberg, F. and Hallberg, M. (2013). GH improves spatial memory and reverses certain anabolic androgenic steroid-induced effects in intact rats. J. Endocrinol. 216, 31-41.
24. Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S. and Binoux, M. (1986). Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal. Biochem. 154, 138-143.
25. Kargi, A. Y. and Merriam, G. R. (2013). Diagnosis and treatment of growth hormone deficiency in adults. Nat. Rev. Endocrinol. 9, 335-345.
26. Kassem, M., Brixen, K., Mosekilde, L., Blum, W. F. and Flyvbjerg, A. (1998). Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women. Clin. Endocrinol. (Oxf.) 49, 747-756.
27. Katter, K., Geurts, A. M., Hoffmann, O., Mátés, L., Landa, V., Hiripi, L., Moreno, C., Lazar, J., Bashir, S., Zidek, V. et al. (2013). Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits. FASEB J. 27, 930-941.
28. Katz, L. E., Liu, F., Baker, B., Agus, M. S., Nunn, S. E., Hintz, R. L. and Cohen, P. (1996). The effect of growth hormone treatment on the insulin-like growth factor axis in a child with nonislet cell tumor hypoglycemia. J. Clin. Endocrinol. Metab. 81, 1141-1146.
29. Katznelson, L., Atkinson, J. L., Cook, D. M., Ezzat, S. Z., Hamrahian, A. H., Miller, K. K.; AACE Acromegaly Task Force (2011). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly - 2011 update: executive summary. Endocr. Pract. 17, 636-646.
30. Keller, A., Wu, Z., Kratzsch, J., Keller, E., Blum, W. F., Kniess, A., Preiss, R., Teichert, J., Strasburger, C. J. and Bidlingmaier, M. (2007). Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur. J. Endocrinol. 156, 647-653.
31. Key, T. J., Appleby, P. N., Reeves, G. K., Roddam, A. W.; Endogenous Hormones and Breast Cancer Collaborative Group (2010). Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 11, 530-542.
32. Kopchick, J. J., Parkinson, C., Stevens, E. C. and Trainer, P. J. (2002). Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23, 623-646.
33. Kopchick, J. J., List, E. O., Kelder, B., Gosney, E. S. and Berryman, D. E. (2014). Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications. Mol. Cell. Endocrinol. 386, 34-45.PubMed
34. Laeger, T., Wirthgen, E., Piechotta, M., Metzger, F., Metges, C. C., Kuhla, B. and Hoeflich, A. (2014). Effects of parturition and feed restriction on concentrations and distribution of the insulin-like growth factor-binding proteins in plasma and cerebrospinal fluid of dairy cows. J. Dairy Sci. 97, 2876-2885.
35. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L. and Butler, A. (2001). The somatomedin hypothesis: 2001. Endocr. Rev. 22, 53-74.
36. Masyuk, T. V., Radtke, B. N., Stroope, A. J., Banales, J. M., Gradilone, S. A., Huang, B., Masyuk, A. I., Hogan, M. C., Torres, V. E. and Larusso, N. F. (2013). Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58, 409-421.
37. Metzger, F., Sajid, W., Saenger, S., Staudenmaier, C., van der Poel, C., Sobottka, B., Schuler, A., Sawitzky, M., Poirier, R., Tuerck, D. et al. (2011). Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I). J. Biol. Chem. 286, 19501-19510.
38. Moller, N. and Jorgensen, J. O. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 30, 152-177.
39. Nason, K. S., Binder, N. D., Labarta, J. I., Rosenfeld, R. G. and Gargosky, S. E. (1996). IGF-II and IGF-binding proteins increase dramatically during rabbit pregnancy. J. Endocrinol. 148, 121-130.
40. NCCLS (2004). Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline NCCLS Document EP5-A2. Wayne, PA: NCCLS.
41. Péter, F., Bidlingmaier, M., Savoy, C., Ji, H. J. and Saenger, P. H. (2012). Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J. Clin. Endocrinol. Metab. 97, 400-407.
42. Petersenn, S., Schopohl, J., Barkan, A., Mohideen, P., Colao, A., Abs, R., Buchelt, A., Ho, Y. Y., Hu, K., Farrall, A. J. et al.; Pasireotide Acromegaly Study Group (2010). Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab. 95, 2781-2789.
43. Pinkert, C. A., Galbreath, E. J., Yang, C. W. and Striker, L. J. (1994). Liver, renal and subcutaneous histopathology in PEPCK-bGH transgenic pigs. Transgenic Res. 3, 401-405.
44. Rosskopf, D., Schwahn, C., Neumann, F., Bornhorst, A., Rimmbach, C., Mischke, M., Wolf, S., Geissler, I., Kocher, T., Grabe, H. J. et al. (2011). The growth hormone - IGF-I axis as a mediator for the association between FTO variants and body mass index: results of the Study of Health in Pomerania. Int. J. Obes. (Lond.) 35, 364-372.
45. Schiller, N. K. and McNamara, D. B. (1999). Balloon catheter vascular injury of the alloxan-induced diabetic rabbit: the role of insulin-like growth factor-1. Mol. Cell. Biochem. 202, 159-167.
46. Sievers, C., Dimopoulou, C., Pfister, H., Lieb, R., Steffin, B., Roemmler, J., Schopohl, J., Mueller, M., Schneider, H. J., Ising, M. et al. (2009). Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin. Endocrinol. (Oxf.) 71, 691-701.
47. Thakur, A., Sase, M., Lee, J. J., Thakur, V. and Buchmiller, T. L. (2000). Ontogeny of insulin-like growth factor 1 in a rabbit model of growth retardation. J. Surg. Res. 91, 135-140.
48. Turner, C. H., Garetto, L. P., Dunipace, A. J., Zhang, W., Wilson, M. E., Grynpas, M. D., Chachra, D., McClintock, R., Peacock, M. and Stookey, G. K. (1997). Fluoride treatment increased serum IGF-1, bone turnover, and bone mass, but not bone strength, in rabbits. Calcif. Tissue Int. 61, 77-83.
49. van der Lely, A. J., Biller, B. M., Brue, T., Buchfelder, M., Ghigo, E., Gomez, R., Hey-Hadavi, J., Lundgren, F., Rajicic, N., Strasburger, C. J. et al. (2012). Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97, 1589-1597.
50. Veldhuis, J. D., Bidlingmaier, M., Anderson, S. M., Evans, W. S., Wu, Z. and Strasburger, C. J. (2002). Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J. Clin. Endocrinol. Metab. 87, 5737-5745.
51. Veldhuis, J. D., Bidlingmaier, M., Bailey, J., Erickson, D. and Sandroni, P. (2010). A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans. J. Clin. Endocrinol. Metab. 95, 3844-3847.
52. Wallis, O. C. and Wallis, M. (1995). Cloning and characterisation of the rabbit growth hormone-encoding gene. Gene 163, 253-256.
53. Wolf, E., Jehle, P. M., Weber, M. M., Sauerwein, H., Daxenberger, A., Breier, B. H., Besenfelder, U., Frenyo, L. and Brem, G. (1997). Human insulin-like growth factor I (IGF-I) produced in the mammary glands of transgenic rabbits: yield, receptor binding, mitogenic activity, and effects on IGF-binding proteins. Endocrinology 138, 307-313.
54. Zapf, J., Schmid, C., Guler, H. P., Waldvogel, M., Hauri, C., Futo, E., Hossenlopp, P., Binoux, M. and Froesch, E. R. (1990). Regulation of binding proteins for insulinlike growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. J. Clin. Invest. 86, 952-961.
55. Zhang, Y. C. and Li, F. C. (2010). Effect of dietary methionine on growth performance and insulin-like growth factor-I mRNA expression of growing meat rabbits. J. Anim. Physiol. Anim. Nutr. (Berl.) 94, 803-809.